March 04, 2015, Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ELEPSIA XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XRTM is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
"Levetiracetam is a very successful and highly effective antiepileptic drug but more than 80% of epilepsy patients require Levetiracetam in does in range of 1000mg to 3000mg resulting in a significant pill burden. Approval of ELEPSIA XRTM as 1000mg and 1500mg once a day tablets will be very useful for these patients and physicians." said Anil Raghavan, Chief Executive Officer of SPARC.
The product will be manufactured by Sun Pharmaceutical Industries Ltd at its Halol (Gujarat) facility in India.
XRTM ELEPSIA XRTM is a novel extended release formulation of Levetiracetam 1000mg and 1500mg. ELEPSIA XRTM has been developed with SPARC's proprietary WRAP MATRIXTM platform technology. Levetiracetam is an antiepileptic drug (AED) indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
Sun Pharma Advanced Research Company Ltd. (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems. More information about the company can be found at www.sunpharma.in.
Tel +91 22 6645 5645, Ext 5606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
Email: [email protected]